Inhibitory monoclonal antibodies against mouse proteases raised in Gene-Deficient mice block proteolytic functions in vivo

Frontiers in Pharmacology

Volumn 3 JUN, Issue , 2012, Pages

  Lund, Ida K ^a,b   Rasch, Morten G ^a,b,c   Ingvarsen, Signe ^a,b   Pass, Jesper ^a,b,c   Madsen, Daniel H ^a,b,d   Engelholm, Lars H ^a,b   Behrendt, Niels ^a,b   Høyer Hansen, Gunilla ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Collagen internalization; Extracellular proteolysis; In vivo models; Mouse monoclonal antibodies; Plasminogen activation

Indexed keywords

EPITOPE; GELATINASE B; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 14 MONOCLONAL ANTIBODY; MATRIX METALLOPROTEINASE 9 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R1; MONOCLONAL ANTIBODY R2; MONOCLONAL ANTIBODY R4; MONOCLONAL ANTIBODY U1; MONOCLONAL ANTIBODY U3; PLASMINOGEN ACTIVATOR INHIBITOR 1 MONOCLONAL ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; UROKINASE RECEPTOR ASSOCIATED PROTEIN MONOCLONAL ANTIBODY; UROKINASE RECEPTOR MONOCLONAL ANTIBODY; VITRONECTIN;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; DRUG HALF LIFE; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC DAMAGE; GENETIC MODEL; HUMAN; IN VIVO STUDY; INTERNALIZATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN TARGETING; THROMBOEMBOLISM;

EID: 84866181263     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00122     Document Type: Article

References (41)

1. Behrendt, N. (2004). The uroki-nase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): mebrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem. 385, 103-136.
2. Behrendt, N., Rønne, E., and Danø, K. (1996). Domain interplay in the urokinase receptor. Requirement for the third domain in high afnity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. Biol. Chem. 271, 22885-22894.
3. Bugge, T. H., Flick,M. J., Danton,M. J., Daugherty, C. C., Rømer, J., Danø, K., Carmeliet, P., Collen, D., and Degen, J. L. (1996). Urokinase-type plasminogen activator is effective in brin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U.S.A 93, 5899-5904.
4. Bugge, T. H., Suh, T. T., Flick, M. J., Daugherty, C. C., Rømer, J., Solberg, H., Ellis, V., Danø, K., and Degen, J. L. (1995). The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270, 16886-16894.
5. Carmeliet, P., Bouche, A., De, C. C., Janssen, S., Pollefeyt, S., Wyns, S., Mulligan, R. C., and Collen, D. (1995). Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes inmice. Ann. N. Y. Acad. Sci. 748, 367-381.
6. Carmeliet, P., Kieckens, L., Schoonjans, L., Ream, B., van,N. A., Prendergast, G., Cole, M., Bronson, R., Collen, D., and Mulligan, R. C. (1993). Plasminogen activator inhibitor-1 gene-decient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92, 2746-2755.
7. Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De, V. R., van den Oord, J. J., Collen, D., and Mulligan, R. C. (1994). Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424.
8. Declerck, P. J., Carmeliet, P., Verstreken, M.,De,C. F., and Collen,D. (1995a). Generation of monoclonal antibodies against autologous proteins in gene-inactivatedmice. J. Biol. Chem. 270, 8397-8400.
9. Declerck, P. J., Verstreken, M., and Collen, D. (1995b). Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb. Haemost. 74, 1305-1309.
10. Declerck, P. J., De, M. M., Alessi, M. C., Baudner, S., Paques, E. P., Preissner, K. T., Müller-Berghaus, G., and Collen, D. (1988). Purication and characterization of a plasminogen activator inhibitor 1 binding pro-tein from human plasma. Identication as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263, 15454-15461.
11. Descamps, F. J.,Martens, E., and Opdenakker, G. (2002). Analysis of gelati-nases in complex biological uids and tissue extracts. Lab. Invest. 82, 1607-1608.
12. Ellis,V., andDanø,K. (1991). Plasminogen activation by receptor-bound urokinase. Semin. Thromb. Hemost. 17, 194-200.
13. Engelholm, L. H., Ingvarsen, S., Jürgensen, H. J., Hillig, T., Madsen, D. H., Nielsen, B. S., and Behrendt, N. (2009). The collagen receptor uPARAP/Endo180. Front. Biosci. 14, 2103-2114.
14. Gårdsvoll, H., Jacobsen, B., Krieg-baum, M. C., Behrendt, N., Engel-holm, L., Østergaard, S., and Ploug, M. (2011). Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J. Biol. Chem. 286, 33544-33556.
15. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Robey, P. G., Poole, A. R., Pidoux, I., Ward, J. M., and Birkedal-Hansen,H. (1999). MT1-MMP-decient mice develop dwarsm, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92.
16. Høyer-Hansen, G., Behrendt,N., Ploug, M., Danø, K., and Preissner, K. T. (1997). The intact urokinase receptor is required for efcient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420, 79-85.
17. Høyer-Hansen, G., and Lund, I. K. (2007). Urokinase receptor variants in tissue and body uids. Adv. Clin. Chem. 44, 65-102.
18. Ingvarsen, S., Madsen, D. H., Hillig, T., Lund, L. R.,Holmbeck,K.,Behrendt, N., and Engelholm, L. H. (2008). Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelati-nase MMP-2 on broblasts and brosarcoma cells. Biol. Chem. 389, 943-953.
19. Jögi, A., Pass, J., Høyer-Hansen, G., Lund, L. R., Nielsen, B. S., Danø, K., and Rømer, J. (2007). Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic brin deposition in tissue-type plasminogen activator decient mice. J. Thromb. Haemost. 5, 1936-1944.
20. Jögi, A., Rønø, B., Lund, I. K., Nielsen, B. S., Ploug, M., Høyer-Hansen, G., Rømer, J., and Lund, L. R. (2010). Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-decient mice. PLoS. One. 5, e12746. doi:10.1371/journal.pone.0012746
21. Jürgensen, H. J., Madsen, D. H., Ingvarsen, S., Melander, M. C., Gårdsvoll, H., Patthy, L., Engelholm, L. H., and Behrendt, N. (2011). A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor uparap/ENDO180. J. Biol. Chem. 286, 32736-32748.
22. Kolaczkowska, E., Arnold, B., and Opdenakker, G. (2008). Gelatinase B/MMP-9 as an inammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specic and cell-specic produc-tion by mast cells, macrophages and neutrophils. Immunobiology 213, 109-124.
23. Liu, S., Aaronson, H., Mitola, D. J., Leppla, S. H., and Bugge, T. H. (2003). Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. U.S.A 100, 657-662.
24. Liu, S., Bugge, T. H., and Leppla, S. H. (2001). Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276, 17976-17984.
25. Lund, I. K., Illemann, M., Thurison, T., Christensen, I. J., and Høyer-Hansen, G. (2011a). uPAR as anticancer target: evaluation of bio-marker potential, histological localization, and antibody-based therapy. Curr. Drug Targets 12, 1744-1760.
26. Lund, I. K., Nielsen, B. S., Almholt, K., Rønø, B., Hald, A., Illemann, M., Green, K. A., Christensen, I. J., Rømer, J., and Lund, L. R. (2011b). Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling. Dev. Biol. 358, 56-67.
27. Lund, I. K., Jögi, A., Rønø, B., Rasch, M. G., Lund, L. R., Almholt, K., Gårdsvoll, H., Behrendt, N., Rømer, J., and Høyer-Hansen, G. (2008). Antibody-mediated targeting of the uPA proteolytic function neutralizes brinolysis in vivo. J. Biol. Chem. 283, 32506-32515.
28. Lund, L. R., Green, K. A., Stoop, A. A., Ploug, M., Almholt, K., Lilla, J., Nielsen, B. S., Christensen, I. J., Craik, C. S., Werb, Z., Danø, K., and Rømer, J. (2006). Plasminogen activation independent of uPA and tPA maintains wound healing in gene-decient mice. EMBO J. 25, 2686-2697.
29. Madsen,D. H., Ingvarsen, S., Jürgensen, H. J., Melander, M. C., Kjøller, L., Moyer, A., Honore, C., Madsen, C. A., Garred, P., Burgdorf, S., Bugge, T. H., Behrendt, N., and Engelholm, L. H. (2011). The non-phagocytic route of collagen uptake: a distinct degradation pathway. J. Biol. Chem. 286, 26996-27010.
30. Madsen, D. H., Jürgensen, H. J., Ingvarsen, S., Melander, M. C., Vainer, B., Egerod, K. L., Hald, A., Rønø, B., Madsen, C. A., Bugge, T. H., Engelholm, L. H., and Behrendt, N. (2012). Endocytic collagen degradation: a novel mechanism involved in the protection against liver brosis. J. Pathol. 227, 94-105.
31. Opdenakker, G., Van Den Steen, P. E., Laureys, G., Hunninck, K., and Arnold, B. (2003). Neutralizing antibodies in gene-defective hosts. Trends Immunol. 24, 94-100.
32. Page-McCaw, A., Ewald, A. J., and Werb, Z. (2007).Matrixmetallopro-teinases and the regulation of tissue remodelling.Nat. Rev.Mol. Cell Biol. 8, 221-233.
33. Pass, J., Jögi, A., Lund, I. K., Rønø, B., Rasch,M. G.,Gårdsvoll,H., Lund, L. R.,Ploug,M.,Rømer,J.,Danø,K.,and Høyer-Hansen, G. (2007). Murine monoclonal antibodies against murine uPA receptor produced in gene-decient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb. Haemost. 97,1013-1022.
34. Rasch, M. G., Pass, J., Illemann, M., Høyer-Hansen, G., and Lund, I. K. (2008). Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies. J. Immunol. Methods 339, 55-65.
35. Smith, H. W., and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat. Rev.Mol. Cell Biol. 11, 23-36.
36. Stevens, L. J., and Page-McCaw, A. (2012). A secreted MMP is required for reepithelialization during wound healing. Mol. Biol. Cell 23, 1068-1079.
37. Sulek, J.,Wagenaar-Miller, R. A., Shire-man, J., Molinolo, A., Madsen, D. H., Engelholm, L. H., Behrendt, N., and Bugge, T. H. (2007). Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer. J. Histochem. Cytochem. 55, 347-353.
38. Van de Craen,B., Scroyen, I.,Abdelnabi, R., Brouwers, E., Lijnen, H. R., Declerck, P. J., and Gils, A. (2011). Characterization of a panel of mon-oclonal antibodies toward mouse PAI-1 that exert a signicant probrinolytic effect in vivo. Thromb. Res. 128, 68-76.
39. Van De Craen, B., Scroyen, I., Vranckx, C., Compernolle, G., Lijnen, H. R., Declerck, P. J., and Gils, A. (2012). Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb. Res. 129, e126-e133.
40. Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hana-han, D., Shapiro, S. D., Senior, R. M., and Werb, Z. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422.
41. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. (1994). Identication of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388.